OpusPoint Partners: Gearing up to Revolutionize Life Science and Healthcare
The future of medicine and healthcare is on the verge of a breakthrough that will mean a better world for mankind. OpusPoint Partners intends to be at the front of this push for improved healthcare and medicine by placing solid investments into recent innovations in the field. The face of life science and healthcare will never be the same.
Founded in 2009 by Michael S. Weiss and Dr. Lindsay Rosenwald, OpusPoint Partners is only one of a group of biotech companies created by these two men. Both Weiss and Rosenwald are zealous adherents to the biotechnology world. The two of them together have over 40 years in experience with life science and biotech investing.
Dr. Lindsay Rosenwald is also the founder of another company named Cougar Biotechnology Inc., a Los Angeles-based company which does research on experimental cancer drugs. Researchers and investors have been following Cougar’s progress as the company turns out some exciting products with great potential. A drug in Cougar’s portfolio may have an impact on prostate cancer late-stage treatment. Johnson & Johnson purchased Cougar Biotech Labs on July 10, 2009 for around one billion dollars.
Lindsay Rosenwald and OpusPoint Partners are particularly interested in building sturdy business alliances with the investment and biotechnology communities. Conducting honest investment and open disclosure policies maintains integrity in the relationships and is also forms an organization’s culture of ethics. These practices create strong relationships when observed by all business and industry partners.
OpusPoint Partners and Lindsay Rosenwald are making alliances with several people, research groups, investors and corporations in an attempt to make large strides in medical innovations that will improve disease treatment. They will also help start-up companies to acquire their goals. With the strength of these relationships, Dr. Lindsay Rosenwald and OpusPoint Partners intend to find, and invest in, the most promising research companies on the verge of very big discoveries.
Dr. Lindsay Rosenwald and OpusPoint Partners are taking biotech investment in a new direction. They are encouraging biotech facilities to enforce a morally-sound set of ideals and really sound business practices, in essence to raise the standards of biotech investing. With these ethics, companies can continue to gain high revenues with low associated risks. The company’s own successes using these same set of values serves as a shining example.
Dr. Rosenwald has been involved with these processes for many years. He has been a biotechnology entrepreneur on Wall Street for over 17 years. He has also been actively engaged with founding and recapitalizing a number of public and private biotech and life sciences companies. He has earned a B.S. in Finance and an M.D. from Pennsylvania State University and the Temple University School of Medicine respectively.
His experience also extends to managing billion-dollar funds for healthcare and biotech investment. The Aries Funds has invested over $1 billion in healthcare under his management while the Orion Fund is completely devoted to private biotech investments, mainly PIPEs.
The basis of OpusPoint’s foundation is to create and sustain a vast network of life science and healthcare groups that uphold standards of integrity and honesty in their work. This mold is something quite rare today where companies often engage in unethical practices for the purpose of gaining more profit.
OpusPoint Partners will be a different kind of company. It will be a company firmly committed to maintaining fairness and ethics in business dealings as well as in the actual testing, manufacture and investigation of drugs.
Following the guidance of Michael Weiss and Dr. Lindsay Rosenwald, OpusPoint Partners has a bright path ahead. With a leadership built upon so much experience and expertise, it is not hard to see that the company will play a key role in the groundbreaking changes to come in medicine and healthcare.
Trying to change what have been the accepted standards in medicine for years will take costly time and energy. It will take money and a very keen dedication to ethics to resist the temptation of choices that may promise higher profit but that have little moral value.
Dr. Rosenwald, though, thinks that it can be done. He uses the company as an example – it has already exceeded its goals by helping to finance over 20 companies in less than two years. It is certain that with the use of the right practices and procedures, there will be very high returns in the worlds of drug research and finance.
Dr. Lindsay Rosenwald is part of the Republican Jewish Coalition Board of Directors. He has also made close alliances to leaders of the biotechnology financing sector. OpusPoint Partners will enjoy a prosperous future with Dr. Rosenwald as its leader.
Related posts: